Cargando…

Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology

Osteoclasts (OCs) have been the unique cell type exhibiting the bone-resorption activity in body. It is important to identify drugs to resist osteoclastogenesis to manage the bone-loss disorders. Huangqi Sanxian decoction (HQSXD) is utilized for the treatment of postmenopausal osteoporosis (PMOP) fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jian-Xin, Cai, Xiao-Qun, Zhao, Ze-Hao, Deng, Yu, Zhou, Zhi-Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225917/
https://www.ncbi.nlm.nih.gov/pubmed/35754697
http://dx.doi.org/10.1155/2022/8769531
_version_ 1784733729613152256
author Shi, Jian-Xin
Cai, Xiao-Qun
Zhao, Ze-Hao
Deng, Yu
Zhou, Zhi-Kun
author_facet Shi, Jian-Xin
Cai, Xiao-Qun
Zhao, Ze-Hao
Deng, Yu
Zhou, Zhi-Kun
author_sort Shi, Jian-Xin
collection PubMed
description Osteoclasts (OCs) have been the unique cell type exhibiting the bone-resorption activity in body. It is important to identify drugs to resist osteoclastogenesis to manage the bone-loss disorders. Huangqi Sanxian decoction (HQSXD) is utilized for the treatment of postmenopausal osteoporosis (PMOP) for a long history in East Asia. This work aimed to examine HQSXD's activity in OC differentiation. Based on staining with tartrate-resistant acid phosphatase (TRAP), it was found that HQSXD suppressed OC generation under the induction of RANKL produced in the bone marrow-derived monocytes/macrophages (BMMs), with no cytotoxic effect. Later analysis like molecular exploration and network pharmacology (NP) suggested the role of HQSXD in suppressing genes associated with osteoclastogenesis via PI3K/Akt-mediated mechanism dose-dependently. This work might illustrate the molecular pharmacological mechanism involved in HQSXD's effect on treating OC-associated disorders. Moreover, NP was found to modernize traditional Chinese medicine (TCM) research.
format Online
Article
Text
id pubmed-9225917
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92259172022-06-24 Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology Shi, Jian-Xin Cai, Xiao-Qun Zhao, Ze-Hao Deng, Yu Zhou, Zhi-Kun Evid Based Complement Alternat Med Research Article Osteoclasts (OCs) have been the unique cell type exhibiting the bone-resorption activity in body. It is important to identify drugs to resist osteoclastogenesis to manage the bone-loss disorders. Huangqi Sanxian decoction (HQSXD) is utilized for the treatment of postmenopausal osteoporosis (PMOP) for a long history in East Asia. This work aimed to examine HQSXD's activity in OC differentiation. Based on staining with tartrate-resistant acid phosphatase (TRAP), it was found that HQSXD suppressed OC generation under the induction of RANKL produced in the bone marrow-derived monocytes/macrophages (BMMs), with no cytotoxic effect. Later analysis like molecular exploration and network pharmacology (NP) suggested the role of HQSXD in suppressing genes associated with osteoclastogenesis via PI3K/Akt-mediated mechanism dose-dependently. This work might illustrate the molecular pharmacological mechanism involved in HQSXD's effect on treating OC-associated disorders. Moreover, NP was found to modernize traditional Chinese medicine (TCM) research. Hindawi 2022-06-08 /pmc/articles/PMC9225917/ /pubmed/35754697 http://dx.doi.org/10.1155/2022/8769531 Text en Copyright © 2022 Jian-Xin Shi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shi, Jian-Xin
Cai, Xiao-Qun
Zhao, Ze-Hao
Deng, Yu
Zhou, Zhi-Kun
Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology
title Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology
title_full Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology
title_fullStr Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology
title_full_unstemmed Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology
title_short Mechanism of Huangqi Sanxian Decoction Inhibiting Osteoclast Differentiation Based on Network Pharmacology
title_sort mechanism of huangqi sanxian decoction inhibiting osteoclast differentiation based on network pharmacology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225917/
https://www.ncbi.nlm.nih.gov/pubmed/35754697
http://dx.doi.org/10.1155/2022/8769531
work_keys_str_mv AT shijianxin mechanismofhuangqisanxiandecoctioninhibitingosteoclastdifferentiationbasedonnetworkpharmacology
AT caixiaoqun mechanismofhuangqisanxiandecoctioninhibitingosteoclastdifferentiationbasedonnetworkpharmacology
AT zhaozehao mechanismofhuangqisanxiandecoctioninhibitingosteoclastdifferentiationbasedonnetworkpharmacology
AT dengyu mechanismofhuangqisanxiandecoctioninhibitingosteoclastdifferentiationbasedonnetworkpharmacology
AT zhouzhikun mechanismofhuangqisanxiandecoctioninhibitingosteoclastdifferentiationbasedonnetworkpharmacology